Nighan Warren JR 4

What Happened

• Nighan Warren Jr., Senior VP, Quality and Regulatory at AngioDynamics, was granted equity awards on July 15, 2026: 17,966 restricted stock units (RSUs) and 17,966 performance rights. Both grants show $0.00 per share (awards, not open‑market trades).
• The RSUs represent contingent rights to receive one share each; the performance rights are contingent on achieving performance goals and may convert to shares if targets are met. No cash changed hands.

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 22, 2026 (appears later than the typical 2-business‑day reporting window).
• Grant amounts: 17,966 RSUs and 17,966 performance rights. Reported price: $0.00 (award).
• Shares owned after transaction: not specified in the filing.
• Footnote highlights:
  • RSU vesting: 25% vest annually on July 15 in 2027, 2028, 2029 and 2030.
  • Performance rights: each right can convert to one share; payout ranges from 0%–200% of target based on total shareholder return vs. peers over a three‑year period, with an additional +/-20% adjustment possible (aggregate potential up to 240% of target).
• No indication of a 10b5-1 plan, tax withholding sale, or immediate sale of shares in this filing.

Context

• These awards are compensation grants (A = Award/Grant), common for executives and typically intended for retention and performance alignment rather than signaling immediate insider buying or selling.
• Performance rights are contingent and may never result in shares if performance metrics are not met; RSUs will convert to shares only as they vest.